Evidence on continuous flow peritoneal dialysis: A review

Joost C. de Vries | Maaike K. van Gelder | Gianni Cappelli | Maria A. Bajo Rubio | Marianne C. Verhaar | Karin G. F. Gerritsen

1Department of Nephrology and Hypertension, University Medical Centre Utrecht, Utrecht, The Netherlands
2Surgical, Medical, Dental, Morphology Sciences, Transplant, Oncology and Regenerative Medicine Department, Division of Nephrology, University of Modena and Reggio Emilia, Modena, Italy
3Nephrology Service, Hospital Universitario La Paz, Institute for Health Research (IdiPAZ), IRSIN, REDinREN, Madrid, Spain

Abstract
Clinical application of continuous flow peritoneal dialysis (CFPD) has been explored since the 1960s, but despite anticipated clinical benefits, CFPD has failed to gain a foothold in clinical practice, among others due to the typical use of two catheters (or a dual-lumen catheter) and large dialysate volumes required per treatment. Novel systems applying CFPD via the existing single-lumen catheter using rapid dialysate cycling may solve one of these hurdles. Novel on-demand peritoneal dialysate generation systems and sorbent-based peritoneal dialysate regeneration systems may considerably reduce the storage space for peritoneal dialysate and/or the required dialysate volume. This review provides an overview of current evidence on CFPD in vivo. The available (pre)clinical evidence on CFPD is limited to case reports/series with inherently nonuniform study procedures, or studies with a small sample size, short follow-up, and no hard endpoints. Small solute clearance appears to be higher in CFPD compared to conventional PD, in particular at dialysate flows ≥100 mL/min using two single-lumen catheters or a double-lumen catheter. Results of CFPD using rapid cycling via a single-lumen catheter are too preliminary to draw any conclusions. Continuous addition of glucose to dialysate with CFPD appears to be effective in reducing the maximum intraperitoneal glucose concentration while increasing ultrafiltration efficiency (mL/g absorbed glucose). Patient tolerance may be an issue since abdominal discomfort and sterile peritonitis were reported with continuous circulation of the peritoneal dialysate. Thus, well-designed clinical trials of longer duration and larger sample size, in particular applying CFPD via the existing catheter, are urgently required.

1 INTRODUCTION

Peritoneal dialysis (PD) has several advantages compared with hemodialysis (HD).1 It allows for continuous and gradual removal of fluid and solutes, does not require vascular access or systemic anticoagulation, and provides more patient autonomy as treatment is performed outside the hospital. In addition, residual kidney function is preserved for a longer period of time compared with HD.2–4 However, PD has several disadvantages: solute clearance is relatively low compared with HD—which is particularly problematic when residual kidney function declines—and technique survival is limited.1,5,6 Main reasons to switch to HD are infectious complications (peritonitis and catheter infection), PD catheter malfunction, and inadequate dialysis (including ultrafiltration failure).7 Chronic exposure to hypertonic
glucose solutions has detrimental effects on the peritoneal membrane which is associated with peritonitis and ultrafiltration failure.\textsuperscript{6,7} Continuous flow peritoneal dialysis (CFPD), based on a continuous flow of “fresh” dialysate along the peritoneal membrane, may address some of these disadvantages and improve both dialysis efficacy and technique survival as outlined below. CFPD has been explored for decades, but despite important anticipated clinical benefits, CFPD has so far failed to gain a foothold in clinical practice, among others due to the need for a separate in- and outflow catheter (either two single-lumen catheters or one double-lumen catheter), the requirement for large dialysate volumes, and higher costs. Novel systems applying CFPD via the existing single-lumen catheter using rapid dialysate cycling and recent progress in sorbent technology allowing use of a small dialysate volume that is continuously regenerated and recirculated in a closed loop have renewed interest in CFPD. Two sorbent-based miniature CFPD devices have recently been tested in first-in-human clinical trials.\textsuperscript{10-12} In addition, a system for on-demand generation of peritoneal dialysate has recently been developed which also allows for a considerable reduction in storage space for dialysate.\textsuperscript{13}

CFPD is presumed to improve clearance in three ways. First, the continuous flow of dialysate along the peritoneal membrane increases the mass transfer area coefficient (MTAC) of solutes, defined as the theoretical maximal diffusive clearance of a solute when no solute accumulation in the PD fluid has occurred.\textsuperscript{14} This is due to elimination of stagnant/saturated layers of dialysate at the peritoneal membrane surface thereby reducing diffusion resistance and an increase of the effective membrane surface area. Second, continuous replacement of the dialysate with fresh (regenerated) PD fluid will maintain a high plasma to dialysate concentration gradient, increasing diffusive solute transport even further. Third, effective dialysis time is increased by reducing the number of exchanges, which limits effective dwell time in automated PD (APD) as this is characterized by multiple (near complete) exchanges in 8 h. A second advantage of CFPD is that it may improve technique survival by prolonging preservation of peritoneal membrane function. With CFPD, a constant glucose concentration for osmotic fluid removal can be applied,\textsuperscript{15} thereby circumventing the need for very high (harmful) initial glucose concentrations, as required with conventional PD to maintain an osmotic gradient up to the end of the dwell. This may prolong preservation of peritoneal membrane integrity since exposure to very high glucose concentrations induces fibrotic changes, eventually resulting in ultrafiltration failure.\textsuperscript{8} Furthermore, CFPD allows for a reduction in the number of exchanges to 1–2 per day versus 4–6 with CAPD/APD, thereby lowering the number of (dis)connections of the peritoneal catheter and/or connections of dialysate bags to the APD machine and therewith the associated risk of (infectious) peritonitis.\textsuperscript{16,17}

The aim of this review is to provide a comprehensive overview of all reports on the efficacy of CFPD in terms of (small) solute clearance and ultrafiltration, especially in the light of recent developments such as the AWAK PD device\textsuperscript{12} and Baxter’s on-demand PD solution system.\textsuperscript{13} Because the available evidence is limited and study design (incl. dialysate flow rates, treatment duration, and dialysis prescription of the control treatment) is highly variable, all article types (i.e., clinical trials, case reports/series, and abstracts) describing in vivo data—either in humans or animals—were included, thus excluding in vitro and in silico data.

## 2 | SELECTION

All human and animal studies/reports on CFPD that reported either clearance, MTAC, or ultrafiltration data were included in this review. CFPD was defined as any form of PD in which a continuous flow of dialysate was established. We included CFPD performed via a single-lumen catheter with alternate in- and outflow of fluid with continuous rapid cycling since for the enhancement of the MTAC of uremic solutes, we deemed the direction of the flow (patient in or out) irrelevant, as both result in a net flow of dialysate passing the peritoneal membrane. In total, 21 records were included for review.\textsuperscript{11,12,18-37}

## 3 | BASELINE CHARACTERISTICS

A summary of the study characteristics and patient demographics is displayed in Table 1, and detailed dialysis prescription is presented in Table 2. Six animal studies were identified and 15 human studies, mostly concerning adult patients with end-stage kidney disease (ESKD) (n = 9 studies) and pediatric patients with acute kidney injury (AKI) (n = 3 studies). Among the human studies, there were six (40%) clinical trials, two (13%) case reports, and seven (47%) case series. “Conventional” PD for comparison with CFPD was performed in eight (53%) out of these 15 clinical studies, but actual results for conventional PD were reported in only seven reports (47%). Follow-up ranged between only one CFPD session and ~11 months. The majority of all included studies (both human and animal) used two single-lumen catheters per subject (57%, n = 12) or one double-lumen catheter (24%, n = 5), and only 19% (n = 4) of the studies employed one single-lumen catheter (with continuous rapid cycling of the dialysate). With regard to catheter location, there were three commonly applied configurations if two catheters were employed: (1) a “one up, one down” configuration (e.g., Amerling et al, Shinaberger et al) in which the inflow catheter was located near the liver, with the outflow in the “standard” location in the lesser (true) pelvis, (2) two catheters on the opposite side to each other (e.g., left vs. right, left upper vs. right lower quadrant; e.g., in Cruz et al, Kostic et al, Raja et al); and (3) in the inflow catheter located between umbilicus and upper iliac crest, with the outflow catheter in the “standard” position (e.g., Raaijmakers et al, Nourse et al). The majority of studies applied high dialysate flows during CFPD, with 12 studies employing flow rates of ≥100 mL/min.\textsuperscript{20,21,23-33} Seven studies (33%) applied CFPD by passing peritoneal dialysate in a single-pass mode through the abdominal cavity,\textsuperscript{18,27,28,34-37} (e.g., by using a CVVH machine), while one study recirculated dialysate from a reservoir.\textsuperscript{29} Thirteen studies (62%) applied dialysate regeneration, either directly with the peritoneal dialysate circuit passing a purification unit based on (modified)
| First author (year) | Article type (study design) | Subjects | Subjects (n [% male]) | Follow-up | Age (years) | Weight (kg) | Transport status |
|---------------------|-----------------------------|----------|-----------------------|-----------|-------------|-------------|-----------------|
| **Animal studies**  |                             |          |                       |           |             |             |                 |
| Geary (1989)        | Animal study                | Pigs     | 16 (NR)               | 1-2 sessions | NR         | 12-14       | NR              |
| Van Gelder (2020)   | Animal study                | Pigs     | 3 (0%)                | 3-7 sessions | NR         | 40-100      | NR              |
| Gordon (1976)       | Animal study                | Dogs     | 4 (NR)                | Unclear    | NR         | 18-44        | NR              |
| Raja (1976)         | Animal study                | Dogs     | 10 (NR)               | Single session | NR       | 22.7-24.9   | NR              |
| Roberts (2016)      | Animal study                | Pigs     | 6 (NR)                | ±1 week    | NR         | 33.5        | NR              |
| Uechi (1993)        | Animal study                | (Mongrel) Dogs | 15 (NR)          | ±3 sessions | NR         | 6.6 ± 0.7   | NR              |
| **Human studies**   |                             |          |                       |           |             |             |                 |
| **Adults**          |                             |          |                       |           |             |             |                 |
| Amerling (2003/2012)| Review/case series          | Patients with AKI or ESKD | 5 (80%)          | 1-5 sessions | 66.8 ± 5.2 | NR          | NR              |
| Charen (2013)       | Case report                 | Patient with AKI | 1 (100%)          | ±7 months   | 61          | 81.4        | NR              |
| Cruz (2001)         | Case series                 | Stable PD patients | 4 (100%)          | Single session | 42 ± 9    | 90.3 ± 25.7 | A (50%), HA (50%) |
| Freida (2003)       | Clinical trial (crossover)  | Stable PD patients | 5 (NR)           | Single session | NR         | NR          | L (20%), LA (20%), HA (20%), H (40%) |
| Htay (2021)         | Clinical trial (FIH)        | Stable PD patients | 10 (67%)         | 3 days (9 sessions) | 58 (35-73) | NR          | H (30%), HA (47%), LA (6.7%), L (6.7%) |
| Mineshima (2000)    | Case series                 | Stable PD patients | 3 (67%)          | 1-5 sessions | 49 ± 3.6   | 47.6 ± 7.6  | NR              |
| Passlick-Deetjen (2001)| Case series              | Stable PD patients | 4 (NR)           | 3 sessions   | NR          | NR          | NR              |
| Raj (2000)          | Clinical trial              | Stable PD patients | 8 (13%)          | Single session | 47.7 ± 14.1 | NR          | NR              |
| Samuelsson (2018)   | Clinical trial (abstract; FIH) | Stable PD patients | 5 (60%)          | Single session | 59.4 ± 10.7 | NR          | NR              |
| ShinaBerger (1965)  | Case series                 | Stable PD patients | 4 (NR)           | Up to 22 sessions | NR         | NR          | NR              |
| Stephen (1976)      | Case series                 | Stable PD patients | 8 (80%)          | 1-11 months  | 40.1 ± 10.5 | NR          | NR              |
| **Pediatric**       |                             |          |                       |           | Age (months) |             |                 |
| Kostic (2010)       | Case report                 | Neonate with AKI | 1 (0%)            | Single session | 0.26       | 2.9         | NR              |
| Nourse (2016)       | Clinical trial (crossover)  | Infants with AKI | 5 (0%)            | Single session | 4.8 ± 3.7  | 5.6 ± 2.3   | NR              |
| Raaijmakers (2011)  | Clinical trial (crossover)  | Children with AKI | 6 (67%)          | Single session | 10.7 ± 10.2 | NR          | NR              |
| Sagy (1999)         | Case series                 | Children with anasarca | 6 (67%)         | Single session | 18.5 ± 34.7 | NR          | NR              |

Note: Values are displayed as mean ± SD, median (range), or fixed value, unless stated otherwise. Abbreviations: A, average; AKI, acute kidney injury; ESKD, end stage kidney disease; FIH, first-in-human clinical trial; H, High; HA, high average; L, low; LA, low-average; NR, not reported; PD, peritoneal dialysis. °Weight range according to inclusion criteria; actual values not reported.
## TABLE 2 Overview of dialysis prescriptions

| First author (year)          | General            | CFPD               | Dialysate glucose | CFPD | Session length (h) | Dialysate regeneration |
|-----------------------------|--------------------|--------------------|-------------------|------|-------------------|------------------------|
|                             | Modality           | Sessions (n)       | Catheter configuration |     |                   |                        |
|                             |                    | CFPD: n | IPD: n          |                   |                   |                        |
| Animal studies              |                    |                   |                   |                   |                   |                        |
| Geary (1989)                | CFPD, IPD          | CFPD: 19 | IPD: 19         | 1 double lumen    | 1.5%               | Short: 2 h Long: 4 h   |
| Van Gelder (2020)           | CFPD, CAPD         | CFPD: 15 | CAPD: 15       | 1 single lumen    | 0.78 ± 0.05% 0.84 ± 0.13% 1.17% | 8 | Yes* |
| Gordon (1976)               | CFPD               | >108               | 2 single lumen    | 1.5%               | 6 | Yes* |
| Raja (1976)                 | CFPD, IPD          | CFPD: 10 | IPD: 10         | 2 single lumen    | 1.5%               | 2 | Yes* |
| Roberts (2016)              | CFPD               | 90                 | 1 single lumen    | 2.5%               | 7 | Yes* |
| Uechi (1993)                | CFPD, IPD          | CFPD: 35 | IPD: 8          | 1 straight catheter (primary) + 1 flat disk catheter (secondary) | 1.3%               | 3 | No |
| Human studies               |                    |                   |                   |                   |                   |                        |
| Adults                      |                    |                   |                   |                   |                   |                        |
| Amerling (2003/2012)        | CFPD               | 16                 | 2 single lumen    | 1.5% (n = 1) NR (n = 4) | 6 (2–24) | Yes |
| Charen (2013)               | CFPD               | NR                 | 1 double lumen    | NR                 | 4–6 | Yes |
| Cruz (2001)                 | CFPD               | 5                  | 2 single lumen    | 1.5%               | 4 | No |
| Freida (2003)               | CFPD, NTPD, NIDP, CAPD | CFPD: 6 | NTPD, NIPD, CAPD: 5 | 2 single lumen    | 1.36%             | 4 | No |
| Htay (2021)                 | CFPD               | 95 (131)c          | 1 single lumen    | 1.21% (IQR 0.99–1.37%) | 35–7 | Yes* |
| Mineshima (2000)            | CFPD, CAPD         | CFPD: 10 | CAPD: 10       | 1 double lumen    | 2.5%, 4.25%        | 6 | Yes |
| Passlick-Deetjen (2001)     | CFPD, IPD          | 12                 | 1 double lumen    | NR                 | 8 | Yes |
| Raj (2000)                  | CFPD, APD          | CFPD: 8 | APD: 8          | 1 single lumen    | 2.5%               | 8 | Yes |
| Samuelsson (2018)           | CFPD               | 5                  | 2 single lumen    | 1.0 ± 0.05%        | 8 | Yes* |
| Shinaberger (1965)          | CFPD, IPD          | CFPD: 33 | IPD: 7          | 2 single lumen    | 1.5%               | NR | Yes |
| Stephen (1976)              | CFPD, IPD          | 91                 | 1 Experimental double lumen Subcutaneous catheter | 1.5%               | 6 | Yes* |
| First author (year)   | General Modality | Sessions (n) | Catheter configuration | Dialysate glucose | CFPD | Session length (h) | Dialysate regeneration |
|----------------------|------------------|--------------|-------------------------|-------------------|------|-------------------|------------------------|
| Pediatric            |                  |              |                         |                   |      |                   |                        |
| Kostic (2010)        | CFPD             | 1            | 2 single lumen          | 1.5%              | CFPD | 6                 | No                     |
| Nourse (2016)        | CFPD, CAPD       | CFPD: 5      | 2 single lumen          | 1.5% (n = 3)      | CAPD | 4.25%             | No                     |
| Raaijmakers (2011)   | CFPD, IPD        | CFPD: 6      | 2 single lumen          | 1.5% (n = 3)      | IPD  | 2.5% (n = 1)      | No                     |
|                      |                  |              |                         |                   |      |                   |                        |
| Sagy (1999)          | CFPD             | NR           | 2 single lumen          | 2.5% (or 4.25%)   |      | 127 ± 60          | No                     |

Note: Values are displayed as mean ± SD, median (range), or fixed value/range, unless stated otherwise.

Abbreviations: APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; CFPD, continuous flow peritoneal dialysis; IQR, interquartile range; (N)IPD, (nocturnal) intermittent peritoneal dialysis; NR, not reported; (N)TPD, (nocturnal) tidal peritoneal dialysis; Qd, effective (dialysate) flow rate; TV, tidal volume.

aDialysate regeneration with (modified) REcirculation DialYsis (REDY) sorbent technology or sorbent technology in general.
bRapid tidal PD was performed, that is, alternate in- and efflux of dialysate via a single-lumen catheter.
c131 sessions were performed, but only 95 were deemed “valid” according to the authors (i.e., session length >3.5 h).
dGlucose concentration 2.5% by default but could be adjusted by the treating physician according to the individual needs of the patient.
eDwell time, dwell volume, and glucose concentration could be adjusted according to the individual needs of the patient.

| First author (year) | CFPD Qd (mL/min) | Total dialysate volume/session (L) | Initial fill volume (L) | CFPD | Conventional Description | Conventional Time-averaged Qd (mL/min) |
|---------------------|------------------|------------------------------------|-------------------------|------|--------------------------|--------------------------------------|
| Animal studies      |                  |                                    |                         |      |                          |                                       |
| Geary (1989)        | 0.40 ± 0.15      | 1.0 ± 0.29                         | 30 ± 1                  |      | Short: one 2-h dwell of 28 ± 3 mL/kg, total volume 379 ± 82 mL | ~0.25                                |
|                     | 0.45 ± 0.09 (mL/kg·min) | 1.7 ± 0.36                         | 30 ± 1 (mL/kg)          |      | Long: two 2-h dwells of 30 ± 3 mL/kg, total volume 742 ± 26 mL | ~0.24 mL/kg/min                       |
| Van Gelder (2020)   | 81 ± 11          | 10–12                              | NR                      |      | One 2-L dwell for 4 h    | 8.3                                  |
| Gordon (1976)       | 40–60–80–100–120 | 28.8–36                            | NR                      |      | NA                       |                                       |
| Raja (1976)         | 66–100–150–200–250 | 10.4–32.5                          | 2.5                     |      | 2-L exchange every 30 min for 2 h | 66                                  |
|                     |                  |                                    |                         |      | 2-L exchange every 20 min for 2 h | 100                                 |
| Roberts (2016)      | NRb              | NR                                 | 1                       |      | NA                       |                                       |
| Uechi (1993)        | 30–60–90–120     | 2                                  | 40 (mL/kg)              |      | One 4-h dwell of 40–60 mL/kg | 0.17–0.25 mL/kg·min                |
| First author (year)               | CFPD | Total dialysate volume/session (L) | Initial fill volume (L) | Description | Conventional | Time-averaged Qd (mL/min) |
|----------------------------------|------|-----------------------------------|-------------------------|-------------|--------------|------------------------|
| Human studies                    |      |                                   |                         |             |              |                        |
| Adults                           |      |                                   |                         |             |              |                        |
| Amerling (2003/2012)             | 200–300 | NR                               | NR                      | NA          |              |                        |
| Charen (2013)                    | 300  | 72–108                            | NR                      | NA          |              |                        |
| Cruz (2001)                      | 200  | 50                                | 2                       | NA          |              |                        |
| Freida (2003)                    | 100–150 | 26–38                            | 2                       | NIPD: 13 L/8 h |
|                                  |      |                                   |                         | CAPD: 4 × 2 L exchange per 24 h | 27 (NTPD/NIPD) | 5.6 (CAPD) |
| Htay (2021)                      | 33.3 (TV = 250 mL)b | ≥7                              | NR                      | NA          |              |                        |
| Mineshima (2000)                 | 100  | NR                                | NR                      | NA          |              |                        |
| Passlick-Deetjen (2001)          | 200  | NR                                | 2                       | Overnight IPD (3 times a week) | NR          |                        |
| Raj (2000)                       | 141 ± 23.7b | 6.2 ± 0.7                       | NR                      | 5 exchanges of (on average) 2.7 L in 8 h | 28 ± 3 |                        |
| Samuelsson (2018)                | NR   | 2                                 | NA                      |             |              |                        |
| Shinaberger (1965)               | 300  | 3–4                               | 2                       | 33          |              |                        |
| Stephen (1976)                   | 100–250 | 37.2–93                         | 1.2–3.0                 | 2 L dwell, 4 L/h for 6–8 h | 0.17–0.25 mL/kg·min |                        |
| Pediatric                        |      |                                   |                         |             |              |                        |
| Kostic (2010)                    | 5    | 1.8                               | 10 (mL/kg)              | NA          |              |                        |
| Nourse (2016)                    | 100 (mL/min/1.73m²) | 4.9                            | 20 (mL/kg)              | APD (n = 2): Exchange of 20 mL/kg every 1.5 h for 11 h (n = 1) | 0.22 mL/kg·min | 0.22 mL/kg·min |
| Raaijmakers (2011)               | 100 (mL/min/1.73m²) | 9.7–14.6                      | 20 (mL/kg)              | CAPD (n = 3): Exchange of 20 mL/kg every 1.5 h for 6 h |                    |                        |
| Sagy (1999)                      | 0.17–0.83 (mL/kg/min) | NR                          | NR                      | Exchange of 20 mL/kg every 1.5 h for 8–16 h | 0.22 mL/kg·min | 0.22 mL/kg·min |

Note: Values are displayed as mean ± SD, median (range), or fixed value/range, unless stated otherwise.

Abbreviations: APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; CFPD, continuous flow peritoneal dialysis; IQR, interquartile range; (N)IPD, (nocturnal) intermittent peritoneal dialysis; NR, not reported; (N)TPD, (nocturnal) tidal peritoneal dialysis; Qd, effective (dialysate) flow rate; TV, tidal volume.

*bDialysate regeneration with (modified) REcirculation Dialysis (REDi) sorbent technology or sorbent technology in general.
*bRapid tidal PD was performed, that is, alternate in- and efflux of dialysate via a single-lumen catheter.
*c131 sessions were performed, but only 95 were deemed “valid” according to the authors (i.e., session length >3.5 h).
*dGlucose concentration 2.5% by default but could be adjusted by the treating physician according to the individual needs of the patient.
*eDwell time, dwell volume, and glucose concentration could be adjusted according to the individual needs of the patient.
In three studies, the secondary dialysate circuit contained a sorbent unit, comprising either only activated carbon or a combination of activated carbon and ion exchangers. In three studies, the secondary dialysate circuit contained a sorbent unit, comprising either only activated carbon or a combination of activated carbon and ion exchangers.

4 | SOLUTE CLEARANCE

4.1 | Small solutes

In animals, direct comparison between CFPD and conventional PD was performed in four out of six studies. In only one study, a considerable increase in small solute clearance was reported (Table 3, Table S1). Uechi et al observed a ~2.5–3.5-fold increase in urea clearance and a ~3-fold increase in creatinine clearance with CFPD at dialysate flow rates of 60–120 mL/min as compared to conventional PD (one dwell of 60 mL/kg in dogs weighing 5.5–7.5 kg. In the other two studies, only a limited increase in small solute clearance was observed. Geary et al reported minimal (28%, 2-h session) or no (4-h session) increase in small solute clearance with CFPD at low dialysate flow rates of ~5 mL/min as compared to static dwells in pigs of ~12–14 kg. Van Gelder et al, using a single-lumen catheter with continuous rapid cycling of dialysate, reported an increase in clearance for creatinine (58%), urea, (45%), phosphate (57%), and potassium (41%) with CFPD (Qd 81 ± 11 mL/min) versus a static dwell (2 L, 4 h) in pigs. However, there was a considerable effect of peritonitis on peritoneal transport, with only potassium clearance being significantly higher with CFPD compared to conventional PD in the absence of peritonitis (i.e., at lower transport status). Raja et al observed a limited increase in urea clearance of 25% (66 mL/min) and 16% (100 mL/min) and in creatinine clearance of 11% (66 mL/min) and 8% (100 mL/min) with CFPD as compared to intermittent PD at similar time-averaged flow rates (Qd 66 and 100 mL/min), which suggests that continuous circulation of dialysate per se may (slightly) increase small solute clearance.

Hijbahn human studies (both adult and pediatric) that evaluated both CFPD and conventional PD (n = 7), CFPD showed a ~3-fold increase in plasma clearance of both urea and creatinine. The available evidence for the effect of CFPD on phosphate clearance is limited and heterogeneous. Raj et al and Nourse et al observed a ~2-fold increase with CFPD as compared with conventional PD, while Freida et al observed a 35% increase. Of note, phosphate concentrations and removal may be influenced by other factors (e.g., intake, use of oral phosphate binders, and circadian variation), making comparison more difficult. Importantly, small solute clearance with CFPD appears to increase at higher dialysate flow rates (Figure 1, Table S2). This was already predicted in a recent in silico study by Öberg et al, though the expected improvement in clearance was highly dependent on the patient’s transport status as well. Furthermore, this study also suggested no added value of increasing flow rates above 200 mL/min, while the included in vivo studies that employed such high dialysate flows still reported further improvement in clearance.

Direct comparison of MTAC—one of the most important determinants of PD efficacy—in CFPD and conventional PD was possible in only two human studies (Freida et al and Raaijmakers et al), both of which reported a ~2.3-fold increase in MTAC for creatinine compared to CAPD (Freida) and IPD (Raaijmakers), respectively. For urea, Freida found a ~1.4-fold increase in MTAC, while Raaijmakers observed an MTAC which was similar for both modalities. Regardless, urea plasma clearance with CFPD was still significantly higher with CFPD compared with conventional PD (15.1 vs. 5.0 mL/min, respectively), although remarkably lower than the creatinine clearance. The theoretical positive relationship between MTAC and Qd, as suggested by Gotch, was only investigated in one subject by Freida et al, who reports a 13% and 47% increase in MTAC of creatinine and urea, respectively, when Qd is increased from 100 to 150 mL/min. In addition, both Freida et al and Cruz et al observed a more pronounced increase in MTAC with CFPD at faster transport status.

4.2 | Middle molecules and protein-bound uremic toxins

Middle molecule clearance in PD is poor, primarily due to the larger size and therewith higher diffusion resistance. Peritoneal clearance of protein-bound uremic toxins is also low since protein-binding restricts passage of the peritoneal membrane. It is difficult to improve clearance of these so-called difficult-to-remove uremic toxins, as displayed by a lack of increase in clearance with a higher volume APD schedule (12 L/day) versus a standard CAPD schedule (8 L/day). For the middle molecules, this may in part be due to the fact that dwell time is more important than dialysate volume or flow employed. However, modeling suggests that CFPD may enhance middle molecule clearance up to a factor of ~2. Removal of middle molecules is primarily driven by convection, which may be facilitated by stable glucose concentrations during CFPD. Only three studies reported β2-microglobulin removal. Freida et al showed a 1.2-fold increase in β2-microglobulin clearance with CFPD compared with conventional PD at a Qd of 100 mL/min, and Samuelsson et al observed a modest and non-significant decrease (8.8%) in β2-microglobulin serum concentrations after 8 h of CFPD (Qd not reported), while Htay et al found a significant reduction of 9.5% after up to 3 days of therapy at a Qd up to 33.3 mL/min. In theory, protein-bound uremic toxin clearance may also increase when removal of the free fraction is improved. However, there are no reports on the effect of CFPD on protein-bound uremic toxin clearance.

5 | ULTRAFILTRATION

An important advantage of CFPD could be improved ultrafiltration at lower (peak) intraperitoneal glucose concentrations, thereby possibly reducing glucose-related toxicity to the peritoneal membrane. Kinetic modeling by Gotch suggests that—in the “average”
## TABLE 3 Overview of outcomes: Solute clearance and mass transfer area coefficient

| First author (year) | General Modality | Subjects (n) | Sessions (n) | Clearances |
|---------------------|------------------|--------------|--------------|------------|
| **Animal studies**  |                  |              |              |            |
| Geary (1989)        | CFPD             | 16           | Short*, n = 9 | 10         |
|                     |                  |              | Long, n = 10 |            |
| Van Gelder (2020)   | CFPD             | 3            | 28           | 5.7 ± 3.4  |
|                     | Conventional (CAPD) | 3        | 15           | 3.6 ± 1.1  |
| Gordon (1976)       | CFPD             | 4            | >108         | 16.3 (9.6–25.7) (n = ≥12 sessions) |
| Raja (1976)         | CFPD             | 10           | 10           | 13 ± 3     |
|                     | Conventional (IPD) | 10       | 10           | 12 ± 2     |
| Roberts (2016)      | CFPD             | 6            | 90           | 5.8 ± 1.1  |
| Uechi (1993)        | CFPD             | 10           | 10           | 7.1 ± 1.8  |
|                     | Conventional (IPD) | 4        | 4            | 2.1 ± 0.2  |
| **Human studies**   |                  |              |              |            |
| Adults              |                  |              |              |            |
| Amerling (2003/2012)| CFPD             | 5            | 16           | NR         |
| Charen (2013)       | CFPD             | 1            | NR           |            |
| Cruz (2001)         | CFPD             | 4            | 5            | 28.2 ± 4.7 |
| Freida (2003)       | CFPD             | 5            | 6            | 22.4 ± 7.5 |
|                     | Conventional (NTPD/CAPD/NIPD) | 5    | 5            | NTPD: 11.1 ± 2.2 |
|                     |                  |              |              | CAPD: 4.5 ± 0.5 |
|                     |                  |              |              | NIPD: 11.0 ± 2.7 |
| Htay (2021)         | CFPD             | 14           | 95           | NR         |
| Mineshima (2000)    | CFPD             | 3            | 10           | NR         |
|                     | Conventional (CAPD) | 3        | 5            | NR         |
| Passlick-Deetjen (2001) | CFPD             | 4            | 12           | 10.6 ± 1.6 |
| Raj (2000)          | CFPD             | 8            | 8            | 22.1 ± 9.4 |
|                     | Conventional (APD) | 8        | 8            | 9.8 ± 5.9  |
| Samuelsson (2018)   | CFPD             | 5            | 5            | 8.1 ± 2.1  |
| Shinaberger (1965)  | CFPD             | 4            | 33           | 34.8 (n = 1 subject, n = 15 sessions) |
|                     | Conventional (IPD) | 4        | 7            | 11.5 ± NR  |
| Stephen (1976)      | CFPD             | 10           | 91           | 24.8 ± 4.9 (n = 8 subjects) |
|                     | Conventional (IPD) | 1        | 1            | 22         |
| First author (year) | General Clearances | Clearances | Creatinine (mL/min) |
|---------------------|--------------------|------------|--------------------|
|                     | Modality | Subjects (n) | Sessions (n) |                     |
| Pediatric           |          |             |               |                    |
| Kostic (2010)       | CFPD     | 1           | 1             | NR                 |
| Nourse (2016)       | CFPD     | 5           | 5             | 33.1 ± 15.5 (mL/min/1.73m²) |
|                     | Conventional (CAPD) | 5 | 5 | 7.4 ± 1.9 (mL/min/1.73m²) |
| Raaijmakers (2011)  | CFPD     | 6           | 6             | 28.8 ± 12.7 (mL/min/1.73m²) |
|                     | Conventional (IPD) | 6 | 6 | 7.6 ± 6.3 (mL/min/1.73m²) |
| Sagy (1999)         | CFPD     | 6           | NR            | NR                 |

Note: Values are displayed as mean ± SD, median (range), or fixed value/range, unless stated otherwise.
Abbreviations: CAPD, continuous ambulatory peritoneal dialysis; CFPD, continuous flow peritoneal dialysis; IPD, intermittent peritoneal dialysis; MTAC, mass transfer area coefficient; NIPD, nocturnal intermittent peritoneal dialysis; NR, not reported; NTPD, nocturnal tidal peritoneal dialysis; Qd, effective (dialysate) flow rate.

aShort: 116 ± 18 min, Long: 250 ± 16 min.
bEarly treatment data during the first month of continuous flow peritoneal dialysis.
cLate treatment data during month 4–6 of continuous flow peritoneal dialysis.

| First author (year) | Clearances | MTAC |
|---------------------|------------|------|
|                     | Urea (mL/min) | Weekly Kt/V | Phosphate (mL/min) | Creatinine (mL/min) | Urea (mL/min) |
| Animal studies      |            |          |                  |                   |               |
| Geary (1989)        | 2.7 ± 0.9  | NR      | 1.7 ± 0.6         | NR                | NR            |
|                     | 1.9 ± 0.63 | NR      | 1.2 ± 0.3         | NR                | NR            |
|                     | 2.1 ± 0.6  | NR      | 1.3 ± 0.3         | NR                | NR            |
|                     | 2.2 ± 0.3  | NR      | 1.2 ± 0.3         | NR                | NR            |
| Van Gelder (2020)   | 8.0 ± 3.2  | NR      | 4.4 ± 3.2         | 7.7 ± 6.1         | 14.0 ± 8.0    |
|                     | 5.5 ± 1.7  | NR      | 2.8 ± 1.1         | 5.2 ± 2.5         | 10.9 ± 3.4    |
| Gordon (1976)       | 33.8 (20.0–57.0) | NR | 12.3 (6.9–20.8) (n = ≥12 sessions) | NR | NR |
| Raja (1976)         | 21 ± 4     | NR      | NR                | NR                | NR            |
|                     | 18 ± 2     | NR      | NR                | NR                | NR            |
| Roberts (2016)      | 12.3 ± 1.6 | 5.2 ± 2.0 | 10.0 ± 2.8       | NR                | NR            |
| Uechi (1993)        | 8.9 ± 2.6  | NR      | 6.9 ± 0.8         | NR                | NR            |
|                     | 2.3 ± 0.4  | NR      | 1.9 ± 0.4         | NR                | NR            |
| Human studies       |            |          |                  |                   |               |
| Adults              |            |          |                  |                   |               |
| Amerling (2003/2012)| 50.6 ± 23.5 (n = 5 pt, n = 16 sessions) | 0.34 ± 0.25 (n = 4 pt, n = 13 sessions) | NR | NR |

Note: Values are displayed as mean ± SD, median (range), or fixed value/range, unless stated otherwise.
| First author (year) | Clearances | MTAC |
|---------------------|------------|------|
|                     | Urea (mL/min) | Weekly Kt/V | Phosphate (mL/min) | Creatinine (mL/min) | Urea (mL/min) |
| Charen (2013)       | 45.4        | 1.0–1.5   | 51.7              | NR                 | NR           |
|                     | 23.5        | 0.96–1.44 | 16.9              | NR                 | NR           |
| Cruz (2001)         | 40.0 ± 5.4  | NR        | NR                | NR                 | 25.2 ± 4.9   |
| Freida (2003)       | 27.8 ± 5.8  | NR        | 11.9 ± NR         | NR                 | 40.4 ± 6.0   |
| Htay (2021)         | NR          | 3.8 ± 1.4 | NR                | NR                 | NR           |
| Mineshima (2000)    | 14.1 ± 4.4  | NR        | NR                | NR                 | NR           |
| Samuelsson (2018)   | 10.6 ± 1.9  | NR        | 9.8 ± 5.2         | NR                 | NR           |
| Shinaberger (1965)  | 57.9 n = 2 subjects; n = 22 sessions | NR | 34.2 ± 9.27 n = 3 subjects; n = 11 sessions | NR | NR |
| Stephen (1976)      | 17.4 ± NR   | NR        | NR                | NR                 | NR           |
|                      | 31–40 (n = 2) | NR | NR | NR | NR |
|                      | 28          | NR        | NR | NR | NR |
| Pediatric            |            |          |                  |                    |              |
| Kostic (2010)       | NR          | NR        | NR                | NR                 | NR           |
| Nourse (2016)       | 22.0 ± 5.1 mL/min/1.73m² | NR | 14.0 ± 11.1 mL/min/1.73m² n = 2 subjects | NR | NR |
| Raaijmakers (2011)  | 6.5 ± 1.1 mL/min/1.73m² | NR | 3.8 ± 1.7 mL/min/1.73m² | NR | NR |
|                     | 15.1 ± 2.1 mL/min/1.73m² | NR | NR | 27.9 ± 16.0 mL/min/1.73m² | NR |
|                     | 5.0 ± 1.7 mL/min/1.73m² | NR | NR | 12.0 ± 10.8 mL/min/1.73m² | NR |
| Sagy (1999)         | NR          | NR        | NR                | NR                 | NR           |

Note: Values are displayed as mean ± SD, median (range), or fixed value/range, unless stated otherwise.
Abbreviations: CAPD, continuous ambulatory peritoneal dialysis; CFPD, continuous flow peritoneal dialysis; IPD, intermittent peritoneal dialysis; MTAC, mass transfer area coefficient; NIPD, nocturnal intermittent peritoneal dialysis; NR, not reported; NTPD, nocturnal tidal peritoneal dialysis; Qd, effective (dialysate) flow rate.

*aShort: 116 ± 18 min, Long: 250 ± 16 min.
*bEarly treatment data during the first month of continuous flow peritoneal dialysis.
*cLate treatment data during month 4–6 of continuous flow peritoneal dialysis.
FIGURE 1  The association between dialysate flow rate (Qd) and clearance of urea and creatinine with continuous flow peritoneal dialysis derived from (A) all animal studies, (B) all human studies, and (C) all studies combined. Of note, all studies which reported both a (fixed) Qd and clearance were included. Each data point represents the mean clearance for creatinine (circles) or urea (squares) at the reported mean effective dialysate flow rate (Qd). If a single study reported data for differing flow rates, each flow rate is displayed as a separate data point in this figure.

6  |  SAFETY

In general, CFPD was well tolerated by patients (Table 5), although abdominal discomfort was commonly reported (Amerling, Charen, Htay, Shinaberger, Stephen) which appeared to be related to the continuous flow (rate) of the dialysate. Htay et al observed abdominal discomfort in 73% of the patients treated with the AWAK PD device at a dialysate flow rate of ~67 mL/min, which resolved either by drainage of dialysate or spontaneously after bowel movement. Stephen et al frequently observed abdominal pain, usually at later stages of a session (after ~3–4 h of a 6-h session) at high dialysate flow rates (>200 mL/min), whereas no discomfort was observed at lower dialysate flow rates. Importantly, cloudy effluent with an elevated number of polymorphonuclear neutrophils was found in a number of subjects (n = 4). As cultures revealed no infectious microorganism, this suggests occurrence of sterile peritonitis, possibly due to mechanical irritation of the peritoneal membrane during CFPD. In contrast, Samuelsson et al specifically state that none of the patients reported any abdominal discomfort, although Qd’s were not reported in these studies, making comparison difficult.

Theoretically, increased ultrafiltration associated with CFPD may result in hypovolemia, enhanced sodium sieving due to increased free water transport, and increased intraperitoneal pressure in the absence of periodic fluid drainage. Enhanced sodium sieving was not observed in the clinical trial with the Carry Life UF System. Calculated sodium concentrations in the ultrafiltrate were similar to those in a peritoneal equilibrium test. Increased intraperitoneal pressure due to overfilling was reported by Nourse et al in one pediatric patient, which was solved by peritoneal fluid drainage. However, the authors did not report which adverse events occurred due to the overfilling. Ultrafiltrate could be periodically or continuously drained during treatment, for example, by setting the

...
peritoneal dialysate outflow slightly higher than the inflow rate.\textsuperscript{18,28,35,36} The theoretical risk of an empty abdomen with continuous drainage due to a discrepancy between outflow and ultrafiltration rate was not reported.

Other reported adverse events were related to the peritoneal catheter, and not specifically to the CFPD technique itself. These included bacterial peritonitis, catheter obstruction, and catheter leakage. Stephen et al used an experimental subcutaneous catheter which resulted in localized peritoneal and subcutaneous abscesses in a number of patients. In addition, Raja et al observed electrolyte disturbances (hypomagnesemia, hyperchloremia, and hypokalemia) which were most likely related to ion exchange by the REDY sorbent system that was used for dialysate regeneration.\textsuperscript{38}

In addition to technique-related safety aspects and adverse events, excessive protein and amino acid losses may be a concern with single-pass CFPD as a result of continuous refreshment of dialysate. Accordingly, Freida et al reported an average total protein loss of 7.25 g (range 5.18–9.66) per 4-h CFPD session (Qd 100 mL/min), whereas this was 5.9 and 6.53 g per 8-h session of NIPD and NTPD (13 L/8 h), respectively, suggesting that protein loss with CFPD is approximately twofold higher. Although no comparison with conventional PD was performed in the study by Stephen et al, protein loss

\begin{table}[h]
\centering
\caption{Overview of CFPD outcomes: ultrafiltration}
\begin{tabular}{|l|c|c|c|c|}
\hline
First author (year) & Modality & UFR (mL/min) & UFV (L) & Dialysate glucose \\
\hline
\textbf{Animal studies} & & & & \\
\hline
Geary (1989) & CFPD & NR & 0.08 ± 0.06 in 2 h & 1.5% \\
 & Conventional (IPD) & NR & 0.14 ± 0.07 in 4 h & 1.5% \\
\hline
Van Gelder (2020) & CFPD & 0.13 ± 0.15 & 0.06 ± 0.07 in 8 h & 0.78 ± 0.05% \\
 & Conventional (CAPD) & 0.19 ± 0.89 & 0.05 ± 0.21 in 4 h & 1.36% \\
Roberts (2016) & CFPD & 3.04 ± 0.83 & 1.28 ± 0.35 in 7 h & 2.5% \\
\hline
\textbf{Human studies} & & & & \\
\hline
\textbf{Adults} & & & & \\
Amerling (2003/2012) & CFPD & 14.38 ± 6.19 (n = 5 pt, n = 14 sessions) & 3.89 ± 0.71 in 6 h (n = 4 pt, n = 11 sessions) & 1.5% (n = 1) \\
 & Conventional (IPD) & NR & 2.36 in 4-6 h & NR \\
Charen (2013) & CFPD & NR & 3.50 in 4-6 h & 1.5% \\
Cruz (2001) & CFPD & 13.38 ± 5.48 & 3.21 ± 1.31 in 4 h & 1.5% \\
Htay (2021) & CFPD & −0.42(−0.60, −0.12)\textsuperscript{a} & 0.66 (0.50–0.98)\textsuperscript{b} & 1.21% (IQR 0.99%–1.37%) \\
Freida (2003) & CFPD & 2.45 ± 1.03 & 0.59 ± 0.49 in 4 h & 1.36% \\
 & NTPD & 0.89 ± 0.45 & 0.43 ± 0.22 in 8 h & 1.36% \\
 & CAPD & NR & 0.45 ± 0.11 in 8 h & 1.36% \\
 & NIPD & 0.94 ± 0.23 & NR & 1.0 ± 0.05% \\
Samuelsson (2018) & CFPD & NR & 0.37 ± 0.05 in 8 h & 1.5% \\
Stephen (1976) & CFPD & NR & 1.8 ± 0.4 in 6 h (n = 8 subjects) & 2.5% \\
\textbf{Pediatric} & & & & \\
Kostic (2010) & CFPD & 1.05 & 0.25 in 6 h & 1.50% \\
Nourse (2016) & CFPD & 3.80 ± 1.71 (mL/min/1.73m\textsuperscript{2}) & 0.18 ± 0.09 in 4.7 ± 1 h & 2.5% \\
 & Conventional (CAPD) & 0.98 ± 0.79 (mL/min/1.73m\textsuperscript{2}) & 0.06 ± 0.06 in 8.8 ± 4 h & 2.5% \\
Raaijmakers (2011) & CFPD & 1.84 ± 1.18 (mL/min/1.73m\textsuperscript{2}) & NR & 2.5%/4.25% (n = 1) \\
 & Conventional (IPD) & 0.20 ± 0.80 (mL/min/1.73m\textsuperscript{2}) & NR & 2.5% (n = 1) \\
Sagy (1999) & CFPD & 4.2 ± 0.9 (mL/kg/h) & 0.56 ± 0.32 (L/24 h) & 2.5% (or 4.25%) \\
\hline
\end{tabular}
\end{table}

Note: Values are displayed as mean ± SD, median (range), or fixed value, unless stated otherwise.

Abbreviations: CFPD, continuous flow peritoneal dialysis; IPD, intermittent peritoneal dialysis; IQR, interquartile range; NIPD, nocturnal intermittent peritoneal dialysis; NR, not reported; NTPD, nocturnal tidal peritoneal dialysis; UFR, ultrafiltration rate; UFV, ultrafiltration volume.

\textsuperscript{a}UFR in patients with residual kidney function (n = 10).

\textsuperscript{b}UFR in patients without residual kidney function (n = 4).
## Table 5: Overview of adverse events related to CFPD

| First author (year) | Peritonitis<sup>a</sup> | Adverse events<sup>b</sup> | Type of event |
|---------------------|--------------------------|----------------------------|---------------|
| **Animal studies**  |                          |                            |               |
| Geary (1989)        | 1 (6%)                   | 7 (44%)                    | Catheter leakage (n = 4) |
|                     |                          |                            | Catheter obstruction (n = 3) |
| Van Gelder (2020)   | 3 (100%)                 | NR                         | NR            |
| Gordon (1976)       | NR                       | NR                         | Electrolyte disturbances (hypernatremia, hyperchloremia, hypokalemia) due to REDY® system |
| Raja (1976)         | NR                       | Not specified              | Abdominal herniation (n = 2) |
| Roberts (2018)      | 1 (17%)                  | 3 (50%)                    | Puncture of PD catheter (n = 1) |
| Uechi (1993)        | NR                       | NR                         | NR            |
| **Human studies**   |                          |                            |               |
| **Adult**           |                          |                            |               |
| Amerling (2003/2012)| 4 (80%)                  | 1 (20%)                    | Dialyzer clogged with fibrin which limited clearance (n = 1) |
|                     |                          |                            | (Abdominal) discomfort (n = 1) |
| Charen (2013)       | 1 (100%)                 | 1 (100%)                   | Catheter leakage |
|                     |                          |                            | Abdominal pain occurred occasionally (resolved after decreasing dialysate flow) |
| Cruz (2001)         | 0 (0%)                   | NR                         | NR            |
| Freida (2003)       | 0 (0%)                   | 0 (0%)                     | None related to dialysis therapy |
| Htay (2021)         | NR                       | Not specified, though at least ≥60% | Abdominal discomfort (n = 9) |
|                     |                          |                            | Abdominal distension/bloating (n = 7) |
|                     |                          |                            | Fibrin in dialysate (n = 5) |
|                     |                          |                            | Elevated blood pressure (n = 4) |
|                     |                          |                            | Neck/shoulder pain/discomfort (n = 2) |
| Minesshima (2000)   | NR                       | NR                         | NR            |
| Johansson (2018)    | NR                       | NR                         | NR            |
| Passlick-Deetjen (2001)| NR                    | NR                         | NR            |
| Raj (2000)          | NR                       | NR                         | NR            |
| Samuelsson (2018)   | NR                       | 0%                         | None related to dialysis therapy |
| Shinaberger (1965)  | NR                       | 0%                         | Mild abdominal discomfort; alleviated by meperidine, lidocaine, and/or reduction of flow rate |
| Stephen (1976)      | 6 (75%)<sup>c</sup>     | Not specified, though at least ≥50% | Mechanical peritonitis (n = 4) |
|                     |                          |                            | No increase in clearance with CFPD due to streaming (n = 1) |
|                     |                          |                            | Moderate–severe abdominal pain at Qd ≥ 200 mL/min (n = 4) |
|                     |                          |                            | Catheter obstruction (n = 2) |
|                     |                          |                            | Infection(s) of the experimental peritoneal catheter (n = 5) |
| **Pediatric**       |                          |                            |               |
| Kostic (2010)       | 0 (0%)                   | 0 (0%)                     | None related to dialysis therapy |
| Nourse (2016)       | NR                       | 3 (60%)                    | Swapped in- and outflow lines, hyperglycemia >20mM requiring insulin therapy (n = 1) |
|                     |                          |                            | Hypokalemia necessitating addition of potassium to dialysate (n = 1) |
| Raaijmakers (2011)  | 0 (0%)                   | 3 (50%)                    | Blockage of inflow catheter which was easily resolved |
| Sagy (1999)         | NR                       | 0 (0%)                     | None related to dialysis therapy |

Abbreviations: IP, intraperitoneal; NR, not reported; Qd, (effective) dialysate flow rate.

<sup>a</sup>Number (percentage) of patients with at least one episode of peritonitis during the study period.

<sup>b</sup>Number (percentage) of patients with at least one adverse events related to dialysis therapy, excluding peritonitis.

<sup>c</sup>Including mechanical peritonitis.
with CFPD was high: on average ~18 g (range 12–32 g) per 6-h session. Protein loss with CFPD may be reduced by application of external dialysate regeneration during which proteins are retained in the peritoneal cavity by an ultrafiltration or dialysis membrane separating the peritoneal dialysate circuit from the dialysate regeneration circuit, therewith preventing large molecules from entering the external dialysate regeneration circuit. Indeed, Samuelsson et al measured a total albumin loss of 2.0 ± 0.6 g per 8-h CFPD session using a sorbent-based external dialysate regeneration system, and Raj et al found comparable protein loss with CFPD and conventional PD (12.9 ± 6.7 vs. 14.7 ± 9.9 g, respectively, per 8-h session) using the dialysate circuit of a HD machine for external dialysate regeneration.

7 | DISCUSSION

CFPD is a promising PD modality which seems to offer improved small solute clearance and improved ultrafiltration efficiency as compared to conventional PD. However, the currently available data make it difficult to draw solid conclusions, in particular with regard to long-term effects.

The currently available data are limited by a variety of factors. First, only a small number of well-controlled clinical trials have been performed. Many reports reviewed here are case series or conference abstracts. These report types are prone to bias (e.g., indication bias and reporting bias), hamper accurate interpretation of the results due to individualized treatments (e.g., different dialysate flow rates within/between subjects) and generally prevent careful review of the methods and results due to brief reporting (abstracts) or high variability (case series). Second, most studies only included a limited number of patients (in this review overall n = 79 for human studies) and/or performed a limited number of dialysis sessions within a limited study duration, with the majority of the studies performing only one or two CFPD session(s) per patient (overall ≥281 sessions) within ≤3 days (range one session to ~11 months). Third, detailed study information was often lacking, for example on patient characteristics (e.g., age, weight, transport status, residual diuresis, and renal clearance), treatment methods (e.g., dialysate flow, initial fill volume, and description of the conventional treatment schedule), and outcome parameters (e.g., solute clearance, MTAC, and UF), complicating accurate interpretation and extrapolation of the study results. Finally, there is considerable heterogeneity regarding the methods employed (e.g., number, type and location of the catheter[s], rate and mode [continuous or rapid cycling] of the dialysate flow, and use of fresh or regenerated dialysate), which also makes it difficult to draw conclusions.

Based on the limited available data, CFPD appears to provide improved (small solute) clearance compared with conventional PD, in particular at higher dialysate flow rates (>100 mL/min) and in patients with high (~average) transport status.40 When performed for 8 h per day, small solute clearances approach the time-averaged clearances of intermittent HD (~11 mL/min for urea [or a weekly standard Kt/V of ~2.2], ~7 mL/min for creatinine with thrice weekly HD).45,46 Therewith, CFPD may become a more attractive alternative for HD, in particular for patients without residual diuresis. Also, improvements in ultrafiltration efficiency were reported in CFPD, therewith potentially reducing glucose-related toxicity to the peritoneal membrane and possibly also adverse systemic metabolic effects of excessive intraperitoneal glucose absorption,47 although this was not explored in any study thus far. In addition, CFPD may be used in the treatment of other causes of hypervolemia as well, such as heart failure. However, there are virtually no data available on long-term CFPD (n = 6 patients with treatment ≥7 months), neither with regard to outcome nor treatment tolerability. Lowering of plasma levels of (pathogenic) uremic toxins and lower daily glucose load,48 as well as improved volume status, may all contribute to improvements in outcome parameters. These may include “hard” parameters such as mortality and (co) morbidity, as well as patient-related (and patient-reported) parameters such as quality of life, necessity for diet restrictions, pill burden, and uremic symptoms. Of note, the ADEMEX trial found that a limited increase in creatinine clearance (~35%) and peritoneal Kt/V (~40%) did not result in a survival advantage.43 Still, the expected large improvement in clearances achieved with CFPD in combination with reduced glucose burden may result in improvements in “hard” endpoints.

As mentioned before, CFPD may theoretically improve technique survival as a result of lower (peak) glucose concentrations—leading to longer preservation of membrane integrity—and lower risk of infective peritonitis due to less (dis)connections of the peritoneal catheter (since less exchanges are required). However, it is unknown what the effect of continuous exposure of the peritoneal membrane to high dialysate flow is on membrane integrity. The occurrence of mechanical peritonitis reported by Stephen et al in four out of eight patients treated with flow rates ≥200 mL/min for 6 h, reports of abdominal discomfort with high dialysate flow rates in several studies, and the marked decrease in dialysis efficacy after ~6 months of CFPD observed by Charen et al (n = 1) give cause for concern and may reflect pathogenic changes to the membrane due to mechanical irritation. Moreover, it is unclear whether maintenance of a high flow rate is feasible on the long term since catheter dysfunction is one of the main complications of PD.49

An important limitation to CFPD is the maintenance of a regulated volume of fluid in the peritoneal cavity. Theoretically, increased ultrafiltration associated with CFPD may result in increased intraperitoneal pressure due to overfilling when periodic or continuous drainage is not performed. Increased intraperitoneal pressure may cause abdominal discomfort, mechanical damage to the peritoneal membrane, and a decrease in solute clearance and ultrafiltration and may compromise respiratory status. On the other hand, continuous drainage without intra-abdominal volume monitoring bares the risk of an empty abdomen when the ultrafiltration rate is lower than expected. This may in theory result in damage to the peritoneal membrane at the catheter tip due to negative pressures. Yet, a system to control and/or monitor intraperitoneal volume during treatment seems important, for example, by measurement of intraperitoneal pressure (e.g., via the abdominal catheter after short cessation of the flow) or
bioimpedance, although it is questionable whether these techniques are accurate enough.

Of note, 83% of CFPD studies used two single-lumen catheters or a double-lumen catheter (not commercially available), while prevalent PD patients have a single-lumen catheter. Thus far, it is unknown whether application of alternate in- and outflow with high flow rates via a single lumen catheter—as applied by Van Gelder (pigs), Roberts (pigs), Htay (patients), and Raj (patients)—can be a reasonable alternative to continuous flow via two catheter(s) (lumens). Findings by Htay and Van Gelder suggest only a limited increase in PD efficacy using this configuration, but results are too preliminary to draw conclusions, and studies providing a direct comparison with a two-catheter setup are lacking. In a recent clinical study, Bergling et al. compared a standard PD regimen (6 × 2 L 1.36% glucose) over 9 h with a novel prescription (7 × 2 L 2.27% glucose + 5 × 2 L 0.1% glucose over 8 h) in 21 patients. The rapid static dwellsw (via a single-lumen catheter) seemed to increase small solute diffusion capacities and hydraulic conductance by 27%, probably related to a stirring effect or a vasodilatation effect due to the time-averaged dialysate flow rate. Theoretically, since MTAC seems to be one of the most important determinants of CFPD efficacy (i.e., clearance), and increases in MTAC may result from high dialysate flow rates along the peritoneal membrane, continuous rapid cycling via a single-lumen catheter using high flow rates may result in high CFPD efficacy. However, a considerable dead volume and high degree of recirculation may limit efficacy of this approach, and two single-lumen catheters or a double-lumen catheter with maximal distance between the tips may be required to ensure proper intraperitoneal fluid mixing, optimize dialysate flow along the peritoneal membrane and maximize the effective membrane area. It is questionable, however, whether use of two PD catheters is feasible in routine clinical practice, as this increases the risk of peritonitis, may limit patient comfort on the long term, and requires an additional invasive procedure in patients who only have a single catheter for conventional PD. In addition, due to the nonpelvic catheter tip location, long-term patency of the second catheter (lumen) may be an issue (e.g., due to omental wrapping or adhesions), although the second catheter (lumen) will primarily be used for inflow, thus reducing the risk of catheter malfunction. However, CFPD with a temporary two-catheter setup may be employed in ICU patients with AKI.

CFPD is more complex than conventional PD. requiring additional materials and machines (e.g., an adapted CVVH machine). The extra equipment and high dialysate volumes are impractical for use at home and render the technique more expensive than conventional PD, which may limit widespread use of the technique. However, the advent of (novel) on-demand peritoneal dialysate generation systems and sorbent-based portable wearable CFPD devices that apply continuous dialysate regeneration may improve simplicity of this technique and result in dialysate volume requirements similar to or lower than in conventional PD. Moreover, possible improved patient outcomes and longer technique survival, postponing the necessity to switch to the more expensive hemodialysis treatment, may outweigh any additional costs of the CFPD technique.

8 CONCLUSION

CFPD shows potential to offer superior small solute clearance and ultrafiltration compared with conventional PD. On-demand dialysate regeneration and sorbent-based portable wearable CFPD devices, currently in the (pre)clinical development phase, may render CFPD applicable for use at home. However, there is a clear need for well-designed (long-term) clinical trials to compare CFPD with conventional PD with regard to PD efficacy, patient outcomes, long-term safety (including tolerability and long-term effects on the peritoneal membrane and transport status), and feasibility and determine the optimal catheter strategy and cost-effectiveness.

ACKNOWLEDGMENTS

This study was supported by the European Union (CORDIAL, Horizon 2020 research and innovation program, grant agreement no. 945207) and by the Dutch Kidney Foundation and Dutch Ministry of Economic Affairs and Climate Policy by means of a PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships (DKF project code PPS08). Open access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

JV, MG, GC, MBR, and KG are involved in the clinical validation of a continuous flow peritoneal dialysis system with dialysate regeneration in cooperation with Nanodialysis B.V. (CORDIAL, Horizon 2020 research and innovation program, grant agreement no. 945207, Dutch Kidney Foundation project PPS08).

AUTHOR CONTRIBUTIONS

JV and MG researched and reviewed literature and were involved in data collection; JV, MG, and KG were involved in data analysis. JV researched and reviewed literature and was involved in conceptualization of the manuscript/study. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

ORCID

Joost C. de Vries https://orcid.org/0000-0002-9953-5069

REFERENCES

1. Sinnakirouchenan R, Holley J. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv Chronic Kidney Dis. 2011;18(6): 428-432. doi:10.1053/J.ACKD.2011.09.001
2. Jansen M, Hart A, Korevaar J, Dekker F, Boeschoten E, Krediet R. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002;62(3):1046-1053. doi:10.1046/J.1523-1755.2002.00505.X
3. Marrón B, Remón C, Pérez-Fontán M, Quirós P, Ortiz A. Benefits of preserving residual renal function in peritoneal dialysis. Kidney Int Suppl. 2008;73(108):S42-S51. doi:10.1038/SJ.KI.5002600
4. Wang A, Lai K. The importance of residual renal function in dialysis patients. Kidney Int. 2006;69(10):1726-1732. doi:10.1038/SJ.KI.5000382
study. *Perit Dial Int*. 2015;35(4):436-442. doi:10.3747/pdi.2013.00202

42. Kim DJ, Do JH, Huh W, Kim YG, Oh HY. Dissociation between clearances of small and middle molecules in incremental peritoneal dialysis. *Perit Dial Int*. 2001;21(5):462-466. doi:10.1177/089686080102100506

43. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. *J Am Soc Nephrol*. 2002;13(5):1307-1320. doi:10.1681/ASN.V1351307

44. Zhu F, Abbas S, Bologa R, Levin N, Kotanko P. Monitoring of intraperitoneal fluid volume during peritoneal equilibration testing using segmental bioimpedance. *Kidney Blood Press Res*. 2019;44(6):1465-1475. doi:10.1159/000503924

45. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. *Am J Kidney Dis*. 2004;44(2):278-285. doi:10.1053/J.AJKD.2004.04.033

46. Rivara MB, Ravel V, Streja E, et al. Weekly standard Kt/V urea and clinical outcomes in home and in-center hemodialysis. *Clin J Am Soc Nephrol*. 2018;13(3):445-455. doi:10.2215/CJN.05680517

47. Holmes C. Glucotoxicity in peritoneal dialysis—solutions for the solution? *Adv Chronic Kidney Dis*. 2007;14(3):269-278. doi:10.1053/J.ACKD.2007.03.009

48. Wu H, Hung K, Huang T, et al. Safety issues of long-term glucose load in patients on peritoneal dialysis—a 7-year cohort study. *PLoS ONE*. 2012;7(1):e30337. doi:10.1371/JOURNAL.PONE.0030337

49. McCormick B, Bargman J. Noninfectious complications of peritoneal dialysis: implications for patient and technique survival. *J Am Soc Nephrol*. 2007;18(12):3023-3025. doi:10.1681/ASN.2007070796

50. Bergling K, de Arteaga J, Ledesma F, Öberg CM. Optimised versus standard automated peritoneal dialysis regimens pilot study (OptiStAR): a randomised controlled crossover trial. *Perit Dial Int*. Published Online. 2022. doi:10.1177/08968608211069232

51. Ersoy FF, Twardowski ZJ, Satalovich RJ, Ketchersid T. A retrospective analysis of catheter position and function in 91 CAPD patients. *Perit Dial Int*. 1994;14(4):409-410. doi:10.1177/089686089401400425

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** de Vries JC, van Gelder MK, Cappelli G, Bajo Rubio MA, Verhaar MC, Gerritsen KGF. Evidence on continuous flow peritoneal dialysis: A review. *Semin Dial*. 2022;35(6):481-497. doi:10.1111/sdi.13097